Buy & Sell GeneDx Holdings Corp (WGS) – GeneDx Holdings Corp Price Today
Key Stats
- $1.75BMarket Cap
- TechnologySector
- -52.16%3M Drawdown
- $1.75BEnterprise Value
- -Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 12 daysTypical Hold Time
GeneDx Holdings Corp (WGS) is currently valued at a market capitalization of $1.75B, with an enterprise value of $1.75B. Over the past 52 weeks, GeneDx Holdings Corp has traded between a low of $34.51 and a high of $167.51, highlighting its annual price range. Over the past three months, GeneDx Holdings Corp has recorded a drawdown of -52.16%, reflecting recent price volatility. On average, investors hold GeneDx Holdings Corp for approximately 12 days, indicating typical investor behavior on the platform.
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Most Recent News
Tourism surges at Hengdian World Studios as Pursuit of Jade tops global C-drama charts.
Hengdian World Studios saw a major spike in visitors after the Chinese drama Pursuit of Jade, filmed mostly at the studio, topped international streaming charts and search volumes in 15 countries. During the May holiday, over 80,000 tourists visited ...

Global sputtering equipment market to reach $4.19B by 2035, driven by semiconductor and solar industry growth.
The global sputtering equipment market is projected to grow from USD 2.41 billion in 2025 to USD 4.19 billion by 2035, at a CAGR of 5.83%. Growth is fueled by rising demand for high-performance semiconductors, flat panel displays, and photovoltaic so...

Japan approves Sanofi's Sarclisa subcutaneous formulation for multiple myeloma treatment
Japan's Ministry of Health has approved Sanofi's Sarclisa (isatuximab) in a subcutaneous form for treating multiple myeloma, including newly diagnosed and relapsed/refractory cases. This approval follows positive results from the phase 3 IRAKLIA stud...
